Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study

BACKGROUND: Patients with severe coronavirus disease 2019 (COVID-19) have elevated levels of acute phase reactants and inflammatory cytokines, including interleukin-6, indicative of cytokine release syndrome (CRS). The interleukin-6 receptor inhibitor tocilizumab is used for the treatment of chimeri...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastroianni, Antonio, Greco, Sonia, Apuzzo, Giovanni, De Santis, Salvatore, Oriolo, Carmela, Zanolini, Alfredo, Chidichimo, Luciana, Vangeli, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329292/
https://www.ncbi.nlm.nih.gov/pubmed/32766535
http://dx.doi.org/10.1016/j.eclinm.2020.100410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329292/
https://www.ncbi.nlm.nih.gov/pubmed/32766535
http://dx.doi.org/10.1016/j.eclinm.2020.100410

Ejemplares similares